Clicky

Kura Oncology, Inc.(KURA) News

Date Title
Sep 30 Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Aug 8 Kura Oncology: Q2 Earnings Snapshot
Aug 8 Kura Oncology Reports Second Quarter 2024 Financial Results
Aug 8 Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
May 14 Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
May 8 2 Incredible Growth Stocks to Buy Hand Over Fist
May 8 Kura Oncology to Participate in Bank of America Securities Healthcare Conference
May 6 Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
May 3 Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ...
May 2 Kura Oncology Reports First Quarter 2024 Financial Results
Apr 25 Kura Oncology to Report First Quarter 2024 Financial Results
Apr 22 Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Apr 10 Kura Oncology to Participate in Stifel Targeted Oncology Forum
Mar 6 Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Feb 2 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1 Chief Medical Officer Stephen Dale Sells Shares of Kura Oncology Inc
Jan 30 Kura Makes Good On Its $150 Million Infusion And Shoots Up 12%
Jan 30 Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Dec 8 Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
Nov 28 Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit